ClinicalTrials.gg

Program

Maraviroc

Also written as “Maraviroc (UK-427,857)”, “maraviroc” and “Maraviroc + Fosamprenavir/ritonavir”.

Its studies are mostly in Acquired Immunodeficiency Syndrome · HIV Infections · Post-Acute COVID-19 Syndrome · Infections · Arthritis, Rheumatoid, led by 4 companies.

Furthest: phase 4, since Apr 23, 200826 company-led studies, 1 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline220 open or runningphase 4since Apr 23, 2008Dec 6, 2004none ahead
Pfizer20 open or runningphase 2since Jan 25, 2007Jan 25, 2007none ahead
HealthBio11 open or runningphase 3since May 7, 2025May 7, 2025Dec 1, 2026phase 3 · NCT06974084
Population Council10 open or runningphase 1since Jan 20, 2015Jan 20, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Dec 6, 2004.

  1. Oct 30, 2008Phase 1 study in Healthy VolunteersPfizer · NCT00783484 · 37 enrolled · Belgium
  2. Nov 12, 2008Phase 2 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT00791700 · 103 enrolled · United States, Brazil, Italy and more
  3. Jan 12, 2009Phase 1 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT00821535 · 12 enrolled · Singapore
  4. Jan 21, 2009Phase 2 study in Human Immunodeficiency Virus-1GlaxoSmithKline · NCT00827112 · 129 enrolled · United States, Germany, Spain
  5. Jan 22, 2010Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT01056874 · 12 enrolled · Singapore
  6. Jun 7, 2010Phase 1 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT01140412 · 14 enrolled · Singapore
  7. Feb 3, 2011Phase 1 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT01290211 · 28 enrolled · Belgium
  8. Mar 22, 2011Phase 4 study in HIV InfectionsGlaxoSmithKline · NCT01327547 · 138 enrolled · United States, Czechia, France and more
  9. Apr 27, 2011Phase 3 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT01345630 · 813 enrolled · United States, Australia, Austria and more
  10. May 10, 2012Phase 1 study in HealthyGlaxoSmithKline · NCT01597895 · 14 enrolled · Belgium
  11. Jan 20, 2015Population Council's first study: phase 1 study in Acquired Immunodeficiency SyndromeNew to Population CouncilPopulation Council · NCT02346084 · 19 enrolled · United States
  12. Jun 16, 2015Phase 1 study in InfectionsGlaxoSmithKline · NCT02480894 · 112 enrolled · United States
  13. Oct 20, 2015Phase 1 study in Healthy SubjectsGlaxoSmithKline · NCT02625207 · 47 enrolled · United States
  14. May 7, 2025HealthBio's first study: phase 3 study in Post-Acute COVID-19 SyndromeNew to HealthBioHealthBio · NCT06974084 · 252 planned · United States

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in Post-Acute COVID-19 SyndromeHealthBio · NCT06974084

TargetBeta

CCR5 →read by rule
“A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV)”NCIt, by rule
“C-C chemokine receptor type 5 antagonist”ChEMBL 37, by rule

Other programs on CCR5

ProgramCompanyFurthest phaseStudies
leronlimabruleCytoDynphase 320

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06974084Post-Acute COVID-19 Syndrome · United States3Not yet recruitingHealthBioDec 1, 2026252
NCT02625207Healthy Subjects · United States1CompletedGlaxoSmithKlineMar 26, 201647
NCT02480894Infections · United States1CompletedGlaxoSmithKlineSep 21, 2015112
NCT02346084Acquired Immunodeficiency Syndrome · United States1CompletedPopulation CouncilDec 201519
NCT01597895Healthy · Belgium1CompletedGlaxoSmithKlineAug 201214
NCT01345630Acquired Immunodeficiency Syndrome · United States, Australia, Austria and more3TerminatedGlaxoSmithKlineAug 2013813
NCT01327547HIV Infections · United States, Czechia, France and more4CompletedGlaxoSmithKlineApr 23, 2013138
NCT01290211Acquired Immunodeficiency Syndrome · Belgium1CompletedGlaxoSmithKlineJun 201128
NCT01140412Acquired Immunodeficiency Syndrome · Singapore1TerminatedGlaxoSmithKlineOct 201014
NCT01056874HIV Infections · Singapore1CompletedGlaxoSmithKlineApr 201012
NCT00827112Human Immunodeficiency Virus-1 · United States, Germany, Spain2CompletedGlaxoSmithKlineJul 2010129
NCT00821535Acquired Immunodeficiency Syndrome · Singapore1CompletedGlaxoSmithKlineMay 200912
NCT00791700Acquired Immunodeficiency Syndrome · United States, Brazil, Italy and more2UNKNOWNGlaxoSmithKlineApr 14, 2015103
NCT00783484Healthy Volunteers · Belgium1CompletedPfizerMay 200937
NCT00782301Hepatitis B · United States, Canada, Poland4WithdrawnGlaxoSmithKlineFeb 20100
NCT00719823Acquired Immunodeficiency Syndrome3WithdrawnGlaxoSmithKlineMay 20100
NCT00717067Acquired Immunodeficiency Syndrome · Germany4CompletedGlaxoSmithKlineNov 200830
NCT00666705Healthy · United States4CompletedGlaxoSmithKlineMar 200818
NCT00643643HIV Infections · Germany, Netherlands, United Kingdom2CompletedGlaxoSmithKlineJun 200341
NCT00634959HIV Infections · United States, Germany, United Kingdom2CompletedGlaxoSmithKline37
NCT00496782HIV Infections · United States, Canada1TerminatedGlaxoSmithKlineOct 200816
NCT00478231Acquired Immunodeficiency Syndrome · Brazil3CompletedGlaxoSmithKlineAug 2010209
NCT00427934Arthritis, Rheumatoid · United States, Australia, Germany and more2TerminatedPfizerOct 2008128
NCT00426660HIV Infections · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineJun 20101,047
NCT00098722HIV Infections · United States, Australia, Belgium and more3CompletedGlaxoSmithKlineApr 2007474
NCT00098293Acquired Immunodeficiency Syndrome · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineApr 2007916

How it is read

Names in the registry

  • “Maraviroc”, 23 entries
  • “Maraviroc (UK-427,857)”, 8 entries
  • “maraviroc”, 5 entries
  • “Maraviroc + Fosamprenavir/ritonavir”, 4 entries
  • “Maraviroc +PF-03716539”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.